{"id":"bnt166a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BNT166a is a personalized neoantigen-targeting mRNA vaccine that encodes patient-specific tumor mutations. It is administered in combination with immunotherapy to prime the immune system to recognize and attack cancer cells expressing these neoantigens, enhancing anti-tumor T-cell responses.","oneSentence":"BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:20:02.366Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (in combination with Merck's Keytruda/pembrolizumab)"},{"name":"Colorectal cancer (in development)"}]},"trialDetails":[{"nctId":"NCT05988203","phase":"PHASE1, PHASE2","title":"A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-09-21","conditions":"Monkeypox","enrollment":96},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BNT166a","genericName":"BNT166a","companyName":"BioNTech SE","companyId":"biontech-se","modality":"Biologic","firstApprovalDate":"","aiSummary":"BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses. Used for Melanoma (in combination with Merck's Keytruda/pembrolizumab), Colorectal cancer (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}